Sandbox 123

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 42: Line 42:
MRSA becomes resistant to β-lactams by acquiring an alternative PBP, PBP2a, that is
MRSA becomes resistant to β-lactams by acquiring an alternative PBP, PBP2a, that is
-
neither bound nor inhibited by β-lactams. Recently, two cephalosporins – <scene name='36/365380/Ceftobiprole/4'>ceftobiprole</scene> and
+
neither bound nor inhibited by β-lactams. Recently, two cephalosporins – <scene name='36/365380/Ceftobiprole/4'>ceftobiprole</scene> and ceftaroline – that have anti-MRSA activity have been developed. Ceftobiprole is able to
-
ceftaroline – that have anti-MRSA activity have been developed. Ceftobiprole is able to
+
inhibit PBP2a because additional chemical groups at the <scene name='36/365380/Ceftobiprole/12'>R2</scene> position of the cephalosporin backbone are able to interact with additional amino acid residues in PBP2a; specifically
inhibit PBP2a because additional chemical groups at the <scene name='36/365380/Ceftobiprole/12'>R2</scene> position of the cephalosporin backbone are able to interact with additional amino acid residues in PBP2a; specifically
<scene name='36/365380/Ceftobiprole/27'>Tyr446 and Met641</scene>. As a result of its tighter binding to PBP2a, ceftobiprole is able to more
<scene name='36/365380/Ceftobiprole/27'>Tyr446 and Met641</scene>. As a result of its tighter binding to PBP2a, ceftobiprole is able to more
Line 55: Line 54:
In addition to TP domain of PBP2a, there is an allosteric domain,highlighted orange, in which the distance between <scene name='36/365380/3zfz_1/17'>the active site and the allosteric site</scene> is 60Å.
In addition to TP domain of PBP2a, there is an allosteric domain,highlighted orange, in which the distance between <scene name='36/365380/3zfz_1/17'>the active site and the allosteric site</scene> is 60Å.
-
Allosteric site serves as a binding site for the substrate <scene name='36/365380/3zfz_1/7'>peptidoglycan</scene>. When the substrate binds to the <scene name='36/365380/3zfz_1/8'>allosteric site</scene> (Tyr105, Asn146, Asp295, Tyr297), a conformational change occurs at the active site, opening it and allowing catalytic action to occur.
+
Allosteric site serves as a binding site for the substrate <scene name='36/365380/3zfz_1/7'>peptidoglycan</scene>. When the substrate binds to the <scene name='36/365380/3zfz_1/18'>allosteric site</scene> (Tyr105, Asn146, Asp295, Tyr297), a conformational change occurs at the active site, opening it and allowing catalytic action to occur.
The medicine, <scene name='36/365380/3zfz_1/12'>ceftaroline</scene>, mimics the substrate at the allosteric site opening the active site, allowing ceftaroline to <scene name='36/365380/3zfz_1/14'>enter and bind noncovalently</scene>.
The medicine, <scene name='36/365380/3zfz_1/12'>ceftaroline</scene>, mimics the substrate at the allosteric site opening the active site, allowing ceftaroline to <scene name='36/365380/3zfz_1/14'>enter and bind noncovalently</scene>.

Revision as of 21:03, 30 April 2014

Drag the structure with the mouse to rotate
Personal tools